LncRNA THOR promotes human renal cell carcinoma cell growth

Biochemical and Biophysical Research Communications
Xueting YeWei-Lie Hu

Abstract

Recent studies have characterized a novel but extremely conserved long non-coding RNA (LncRNA) THOR. THOR directly associates with insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) to promote mRNA stabilization of key pro-cancerous genes. Here, we show that THOR is expressed in human renal cell carcinoma (RCC) tissues and established/primary human RCC cells. It was not detected in normal renal tissues nor in HK-2 and primary human renal epithelial cells. THOR silencing (by targeted siRNAs) or CRISPR/Cas9 knockout inhibited RCC cell growth, viability and proliferation in vitro. Reversely, forced over-expression of THOR promoted RCC cell survival and proliferation. IGF2BP1-regulated genes, including IGF2, GLI1 and Myc, were downregulated by THOR silencing or knockout, but they were upregulated after THOR over-expression. In vivo, THOR-knockout 786-O tumors grew significantly slower than the control tumors in nude mice. THOR expression promotes RCC cell growth in vitro and in vivo. THOR could be a novel and important therapeutic target for human RCC.

Citations

Nov 20, 2018·Molecular Oncology·Lotteke J Y M SwierJoost Kluiver
Feb 25, 2020·The EMBO Journal·Ruth L SealElspeth A Bruford
Mar 19, 2020·Frontiers in Oncology·Yujia WangXian Jiang
Nov 27, 2019·Cell Death & Disease·Jinqian LiangMing-Sheng Tan
May 13, 2020·Cell Death & Disease·Ming XuJin Zhu
Aug 15, 2020·Cell Death & Disease·Hongmei LiuZhanjun Li
Sep 13, 2020·Cell Death & Disease·Jian ZhangLong Cheng
Jul 28, 2019·Biochemical and Biophysical Research Communications·Chang SuYiou Cao
Apr 20, 2019·Biochemical and Biophysical Research Communications·Zheng-Wei LiHai-Hui Qin
Aug 28, 2021·Biomedicines·Ekaterina Mikhailovna StasevichAnton Markovich Schwartz
Aug 19, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yamin Shang
Dec 7, 2021·Frontiers in Oncology·Peng-Fei JiaoGao-Fei Ren
Sep 19, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Hu SongJun Song

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.